Tags

Type your tag names separated by a space and hit enter

(-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Cancer Sci. 2009 Oct; 100(10):1957-62.CS

Abstract

The receptor tyrosine kinase vascular endothelial growth factor (VEGF) receptor (VEGFR) plays an important role in tumor angiogenesis of hepatocellular carcinoma (HCC). (-)-Epigallocatechin gallate (EGCG), the major biologically active component of green tea, inhibits growth in a variety of human cancer cells by inhibiting the activation of several types of receptor tyrosine kinases. In this study, we examined the effects of EGCG on the activity of the VEGF-VEGFR axis in human HCC cells. The levels of total and phosphorylated (i.e. activated) form of VEGFR-2 protein (p-VEGFR-2) were observed to increase in a series of human HCC cell lines in comparison to the Hc normal human hepatocytes. EGCG preferentially inhibited the growth of HuH7 HCC cells, which express constitutive activation of the VEGF-VEGFR axis, in comparison to Hc cells. Treatment of HuH7 cells with EGCG caused a time- and dose-dependent decrease in the expression of VEGFR-2 and p-VEGFR-2 proteins. The production of VEGF from HuH7 cells was reduced by treatment with EGCG. Drinking of EGCG significantly inhibited the growth of HuH7 xenografts in nude mice and this was associated with inhibition of the activation of VEGFR-2 and its related downstream signaling molecules, including ERK and Akt. EGCG drinking also decreased the expression of Bcl-x(L) protein and VEGF mRNA in the xenografts. These findings suggest that EGCG can exert, at least in part, its growth-inhibitive effect on HCC cells by inhibiting the VEGF-VEGFR axis. EGCG might therefore be useful in the treatment of HCC.

Authors+Show Affiliations

Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19558547

Citation

Shirakami, Yohei, et al. "(-)-Epigallocatechin Gallate Suppresses the Growth of Human Hepatocellular Carcinoma Cells By Inhibiting Activation of the Vascular Endothelial Growth Factor-vascular Endothelial Growth Factor Receptor Axis." Cancer Science, vol. 100, no. 10, 2009, pp. 1957-62.
Shirakami Y, Shimizu M, Adachi S, et al. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci. 2009;100(10):1957-62.
Shirakami, Y., Shimizu, M., Adachi, S., Sakai, H., Nakagawa, T., Yasuda, Y., Tsurumi, H., Hara, Y., & Moriwaki, H. (2009). (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Science, 100(10), 1957-62. https://doi.org/10.1111/j.1349-7006.2009.01241.x
Shirakami Y, et al. (-)-Epigallocatechin Gallate Suppresses the Growth of Human Hepatocellular Carcinoma Cells By Inhibiting Activation of the Vascular Endothelial Growth Factor-vascular Endothelial Growth Factor Receptor Axis. Cancer Sci. 2009;100(10):1957-62. PubMed PMID: 19558547.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. AU - Shirakami,Yohei, AU - Shimizu,Masahito, AU - Adachi,Seiji, AU - Sakai,Hiroyasu, AU - Nakagawa,Takayuki, AU - Yasuda,Yoichi, AU - Tsurumi,Hisashi, AU - Hara,Yukihiko, AU - Moriwaki,Hisataka, Y1 - 2009/06/04/ PY - 2009/6/30/entrez PY - 2009/6/30/pubmed PY - 2009/10/10/medline SP - 1957 EP - 62 JF - Cancer science JO - Cancer Sci VL - 100 IS - 10 N2 - The receptor tyrosine kinase vascular endothelial growth factor (VEGF) receptor (VEGFR) plays an important role in tumor angiogenesis of hepatocellular carcinoma (HCC). (-)-Epigallocatechin gallate (EGCG), the major biologically active component of green tea, inhibits growth in a variety of human cancer cells by inhibiting the activation of several types of receptor tyrosine kinases. In this study, we examined the effects of EGCG on the activity of the VEGF-VEGFR axis in human HCC cells. The levels of total and phosphorylated (i.e. activated) form of VEGFR-2 protein (p-VEGFR-2) were observed to increase in a series of human HCC cell lines in comparison to the Hc normal human hepatocytes. EGCG preferentially inhibited the growth of HuH7 HCC cells, which express constitutive activation of the VEGF-VEGFR axis, in comparison to Hc cells. Treatment of HuH7 cells with EGCG caused a time- and dose-dependent decrease in the expression of VEGFR-2 and p-VEGFR-2 proteins. The production of VEGF from HuH7 cells was reduced by treatment with EGCG. Drinking of EGCG significantly inhibited the growth of HuH7 xenografts in nude mice and this was associated with inhibition of the activation of VEGFR-2 and its related downstream signaling molecules, including ERK and Akt. EGCG drinking also decreased the expression of Bcl-x(L) protein and VEGF mRNA in the xenografts. These findings suggest that EGCG can exert, at least in part, its growth-inhibitive effect on HCC cells by inhibiting the VEGF-VEGFR axis. EGCG might therefore be useful in the treatment of HCC. SN - 1349-7006 UR - https://www.unboundmedicine.com/medline/citation/19558547/____Epigallocatechin_gallate_suppresses_the_growth_of_human_hepatocellular_carcinoma_cells_by_inhibiting_activation_of_the_vascular_endothelial_growth_factor_vascular_endothelial_growth_factor_receptor_axis_ L2 - https://doi.org/10.1111/j.1349-7006.2009.01241.x DB - PRIME DP - Unbound Medicine ER -